Revive Therapeutics (CSE: RVV) is one step closure to commencing its phase three clinical trials for the use of Bucillamine in patients with mild-moderate COVID-19. The company announced this morning that its protocol to evaluate the safety and efficacy of the drug has received approval from an independent institutional review board, pushing the firm to the next step in the clinical trial process.
The firm recently saw this protocol approved by Advarra, a premier service provider within the space, just days after submitting for approval. Advarra has been approved by the FDA to formally review and monitor biomedical research involving human subjects.
An independent review board essentially has the authority to approve, require modification, or disapprove research and their protocols. The purpose of such a review is to ensure both before and during the clinical trials that appropriate steps are being taken to protect the rights and welfare of the human test subjects being used in the research.
Now that Revive has its approval from an independent review board, the company can begin to recruit US clinical study sites more efficiently. It also enables the company to move forward with its clinical trials, which have advanced to phase three under the investigational new drug application that was approved by the US Food and Drug Administration in July.
Revive Therapeutics last traded at $0.28 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
